Grace Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Grace Therapeutics, Inc. (Nasdaq: GRCE) is a late-stage biopharmaceutical company focused on developing and commercializing novel drug delivery technologies and pharmaceutical products for rare and orphan diseases, including aneurysmal subarachnoid hemorrhage, ataxia-telangiectasia, and postherpetic neuralgia. Founded in 2002 and headquartered in Princeton, New Jersey, the company offers a pipeline of clinical-stage assets comprising GTx-104, an intravenous infusion formulation of nimodipine targeting aneurysmal subarachnoid hemorrhage; GTx-102, an oral mucosal spray of betamethasone to improve neurological symptoms in ataxia-telangiectasia; and GTx-101, a topical bioadhesive film-forming bupivacaine spray for pain associated with postherpetic neuralgia; each granted Orphan Drug Designation by the U.S. FDA, providing seven years of marketing exclusivity post-approval and supported by over 40 granted and pending patents worldwide. Grace Therapeutics operates primarily in the United States with a focus on neurological disorders underserved by current therapies. In October 2024, the company changed its name from Acasti Pharma Inc. to better reflect its scientific advancements and mission; recently secured up to $30 million in private placement financing led by Nantahala Capital and ADAR1 Partners, LP in February 2025 to support pre-commercial development of GTx-104, followed by $4 million from warrant exercises in October 2025 and a Type C meeting with the FDA on its planned New Drug Application submission as announced in its 2025 fiscal year-end results.
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
Grace Therapeutics: Assessing The Path Forward For GTx-104
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
US FDA declines to approve Grace Therapeutics' drug for a type of stroke
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Expands By 300.8%
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Thursday